Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/NontargetedLung).
